FRAIL-AF
2024
Safety of Switching From a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation
In 1,330 frail elderly patients with atrial fibrillation stable on a vitamin K antagonist, switching to a DOAC increased major or clinically relevant bleeding compared with continuing the vitamin K antagonist.
Result
Efficacy: Composite of major or clinically relevant non-major bleedingHR 1.69 (95% CI 1.23-2.32)
Below 1 favours switching to a DOAC, above 1 favours continuing the vitamin K antagonist.
- Absolute difference
- 5.9 points
- NNH
- 17
Absolute difference and NNH are derived from the event rates.
Also reported: Switching to a DOAC caused more bleeding than continuing a VKA, without offsetting thromboembolism reduction.
- Subtopic
- DOAC switch
- Design
- Open-label superiority RCT with blinded adjudication, stopped early
- Relevance
- Important: one of several pillars.
- Cited in
- ESC 2024 AF
- Source
- Joosten LPT, et al. Circulation. 2024;149(4):279-289.doi 10.1161/CIRCULATIONAHA.123.066485
Discussion & critique
Applies to frail patients already stable on a VKA and does not argue against starting DOACs de novo. Challenged routine VKA-to-DOAC switching in frail elderly AF patients.